Buscar
ADC Therapeutics SA
ADCTAñadir a la lista de seguimiento
1.070USD
-0.040-3.60%
Cierre 09-11 16:00（ET）
135.08MCap. mercado
PérdidaP/E TTM
Fuera de horario 19:00 (ET)1.070USD+0.005+0.47%
Fuera de horario 19:00 (ET)Más Datos de ADC Therapeutics SA Compañía
ADC Therapeutics SA is a Switzerland-based clinical-stage oncology drug discovery and development company. It develops antibody drug conjugates (ADCs) for the treatment of both solid and hematological cancers. It employs monoclonal antibodies specific to particular tumor antigens conjugated to a class of pyrrolobenzodiazepine (PBD)-based warheads to selectively target and kill cancer cells. The Company has multiple PBD-based ADCs in ongoing clinical trials, ranging from first in human to pivotal Phase II clinical trials, and numerous preclinical ADCs in development. Its main drug candidates are ADCT-301 for the treatment of lymphoma and leukemia and ADCT-402 for the treatment of non-Hodgkin’s lymphoma and B-cell leukemia. It serves customers in the United States, Switzerland, and the United Kingdom.
Perfil de ADC Therapeutics SA
Símbolo de cotizaciónADCT
Nombre de la empresaADC Therapeutics SA
Fecha de salida a bolsaMay 15, 2020
Director ejecutivoMallik (Ameet)
Número de empleados263
Tipo de seguridadOrdinary Share
Fin del año fiscalMay 15
DirecciónBiopole
CiudadEPALINGES
Bolsa de valoresNASDAQ OMX NASDAQ Basic NYSE
PaísSwitzerland
Código postal1066
Teléfono41216530200
Sitio Webhttps://adctherapeutics.com/
Símbolo de cotizaciónADCT
Fecha de salida a bolsaMay 15, 2020
Director ejecutivoMallik (Ameet)
Ejecutivos de ADC Therapeutics SA
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Ameet Mallik
Mr. Ameet Mallik
Chief Executive Officer, Director
Chief Executive Officer, Director
3.02M
+22.35%
Mr. Ameet Mallik
Mr. Ameet Mallik
Chief Executive Officer, Director
Chief Executive Officer, Director
3.02M
+22.35%
Mr. Ron R. Squarer
Mr. Ron R. Squarer
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
1.61M
+1.85%
Mr. Ron R. Squarer
Mr. Ron R. Squarer
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
1.61M
+1.85%
Dr. Mohamed Zaki, M.D., Ph.D.
Dr. Mohamed Zaki, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
1.16M
+18.47%
Dr. Mohamed Zaki, M.D., Ph.D.
Dr. Mohamed Zaki, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
1.16M
+18.47%
Mr. Jose (Pepe) Carmona
Mr. Jose (Pepe) Carmona
Chief Financial Officer
Chief Financial Officer
899.39K
+22.65%
Mr. Jose (Pepe) Carmona
Mr. Jose (Pepe) Carmona
Chief Financial Officer
Chief Financial Officer
899.39K
+22.65%
Mr. Peter J. Graham
Mr. Peter J. Graham
Chief Legal and Compliance Officer and Secretary
Chief Legal and Compliance Officer and Secretary
802.67K
+27.55%
Mr. Peter J. Graham
Mr. Peter J. Graham
Chief Legal and Compliance Officer and Secretary
Chief Legal and Compliance Officer and Secretary
802.67K
+27.55%
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Ameet Mallik
Mr. Ameet Mallik
Chief Executive Officer, Director
Chief Executive Officer, Director
3.02M
+22.35%
Mr. Ameet Mallik
Mr. Ameet Mallik
Chief Executive Officer, Director
Chief Executive Officer, Director
3.02M
+22.35%
Mr. Ron R. Squarer
Mr. Ron R. Squarer
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
1.61M
+1.85%
Mr. Ron R. Squarer
Mr. Ron R. Squarer
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
1.61M
+1.85%
Dr. Mohamed Zaki, M.D., Ph.D.
Dr. Mohamed Zaki, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
1.16M
+18.47%
Dr. Mohamed Zaki, M.D., Ph.D.
Dr. Mohamed Zaki, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
1.16M
+18.47%
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de ADC Therapeutics SA?
Los cinco principales accionistas de ADC Therapeutics SA son: Mr. Ameet Mallik
¿Cuántas instituciones poseen acciones de ADC Therapeutics SA (ADCT)?
A fecha de 2026Q1, 205 instituciones poseen acciones de ADC Therapeutics SA, con un valor de mercado combinado de aproximadamente 87.78M, lo que representa el 69.09% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en -1768527.00.
¿Cuál es la mayor fuente de ganancias de ADC Therapeutics SA?
El 2026Q1, el segmento empresarial Product generó la ganancia más alta para ADC Therapeutics SA, ascendiendo a 18.63M y representando el 96.81% de la ganancia total.